Initial Filing Analysis Error
Initial Filing Analysis Error
Chen Shiping (Chief Operating Officer) reported special transactions (Non-P/S).
Chen Shiping (Chief Operating Officer) reported special transactions (Non-P/S).
https://www.stocktitan.net/news/ALMR/jama-study-using-alamar-biosciences-nulisa-assay-links-blood-e-mtbr-qme2umpj1bts.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/jama-study-using-alamar-biosciences-nulisa-assay-links-blood-e-mtbr-qme2umpj1bts.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/alamar-biosciences-highlights-nulisa-data-in-46-presentations-at-4tyygqom09j6.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/alamar-biosciences-highlights-nulisa-data-in-46-presentations-at-4tyygqom09j6.html?utm_source=stocktitan-bluesky&utm_medium=social
Qiming Corporate GP VI, Ltd. () sold 187,636 shares at an average price of $30.2523 per common share. (Date: 2026-11-02)
Qiming Corporate GP VI, Ltd. () sold 187,636 shares at an average price of $30.2523 per common share. (Date: 2026-11-02)
https://www.stocktitan.net/news/ALMR/alamar-biosciences-partners-with-gsk-on-large-scale-proteomic-study-8qoubarnmmii.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/alamar-biosciences-partners-with-gsk-on-large-scale-proteomic-study-8qoubarnmmii.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/alamar-biosciences-reports-third-quarter-2026-financial-results-and-6posg2vmdcac.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/alamar-biosciences-reports-third-quarter-2026-financial-results-and-6posg2vmdcac.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/update-alamar-biosciences-and-nightingale-health-to-lead-uk-biobank-ijpwxzlsj1jr.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/update-alamar-biosciences-and-nightingale-health-to-lead-uk-biobank-ijpwxzlsj1jr.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/alamar-biosciences-and-nightingale-health-to-lead-uk-biobank-80-000-81xtz55fvr3e.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/alamar-biosciences-and-nightingale-health-to-lead-uk-biobank-80-000-81xtz55fvr3e.html?utm_source=stocktitan-bluesky&utm_medium=social
Qiming Corporate GP VI, Ltd. () sold 185,731 shares at an average price of $32.1373 per common share. (Date: 2026-10-28)
Qiming Corporate GP VI, Ltd. () sold 185,731 shares at an average price of $32.1373 per common share. (Date: 2026-10-28)
https://www.stocktitan.net/news/ALMR/emory-researchers-identify-blood-protein-signature-that-detects-als-k60hfjwu2528.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/emory-researchers-identify-blood-protein-signature-that-detects-als-k60hfjwu2528.html?utm_source=stocktitan-bluesky&utm_medium=social
Qiming Corporate GP VI, Ltd. () sold 280,458 shares at an average price of $30.5563 per common share. (Date: 2026-10-26)
Qiming Corporate GP VI, Ltd. () sold 280,458 shares at an average price of $30.5563 per common share. (Date: 2026-10-26)
Qiming Corporate GP VI, Ltd. () sold 342,626 shares at an average price of $29.9250 per common share. (Date: 2026-10-22)
Qiming Corporate GP VI, Ltd. () sold 342,626 shares at an average price of $29.9250 per common share. (Date: 2026-10-22)
Qiming Corporate GP VI, Ltd. () sold 217,512 shares at an average price of $27.3547 per common share. (Date: 2026-10-20)
Qiming Corporate GP VI, Ltd. () sold 217,512 shares at an average price of $27.3547 per common share. (Date: 2026-10-20)
Qiming Venture Partners VI, L.P., a Affiliate, filed a notice of intent to sell 1,558,858 shares of common stock, valued at approximately $36,664,000.00, on 10/14/2026.
Qiming Venture Partners VI, L.P., a Affiliate, filed a notice of intent to sell 1,558,858 shares of common stock, valued at approximately $36,664,000.00, on 10/14/2026.
Qiming Venture Partners VIII Investments, LLC, a Affiliate, filed a notice of intent to sell 363,729 shares of common stock, valued at approximately $8,555,000.00, on 10/14/2026.
Qiming Venture Partners VIII Investments, LLC, a Affiliate, filed a notice of intent to sell 363,729 shares of common stock, valued at approximately $8,555,000.00, on 10/14/2026.
Qiming Managing Directors Fund VI, L.P., a Affiliate, filed a notice of intent to sell 41,945 shares of common stock, valued at approximately $987,000.00, on 10/14/2026.
Qiming Managing Directors Fund VI, L.P., a Affiliate, filed a notice of intent to sell 41,945 shares of common stock, valued at approximately $987,000.00, on 10/14/2026.
Qiming Venture Partners VIII-HC, L.P., a Affiliate, filed a notice of intent to sell 435,468 shares of common stock, valued at approximately $10,242,000.00, on 10/14/2026.
Qiming Venture Partners VIII-HC, L.P., a Affiliate, filed a notice of intent to sell 435,468 shares of common stock, valued at approximately $10,242,000.00, on 10/14/2026.
https://www.stocktitan.net/news/ALMR/alamar-biosciences-to-report-third-quarter-2026-financial-results-on-1qg510mxlod8.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/alamar-biosciences-to-report-third-quarter-2026-financial-results-on-1qg510mxlod8.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/lancet-neurology-study-using-alamar-biosciences-technology-reveals-jd0m1htdiwxk.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALMR/lancet-neurology-study-using-alamar-biosciences-technology-reveals-jd0m1htdiwxk.html?utm_source=stocktitan-bluesky&utm_medium=social